安科生物(300009.SZ)：参股公司PA3-17注射液新增适应症申报临床试验获得受理

Core Viewpoint - Anke Biotech (300009.SZ) announced that its affiliated companies, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., have received acceptance for a clinical trial application for the PA3-17 injection targeting relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/RT-ALL/LBL) in children and adolescents from the National Medical Products Administration [1] Group 1 - Anke Biotech's affiliated companies are involved in the development of PA3-17 injection [1] - The clinical trial application for PA3-17 has been accepted, indicating progress in the drug development process [1] - The targeted indication for the clinical trial is specifically for children and adolescents suffering from R/RT-ALL/LBL [1]